Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes.

Ana M González-LleóRosa M Sánchez-HernándezNúria PlanaDaiana IbarretxePere RehuesJosep RibaltaDídac LlopAna M WägnerLluís MasanaMauro Boronat

Published in: Cardiovascular diabetology (2024)

A nonsignificant increase in NODM occurred in the PCSK9iG, particularly in patients with prediabetes, compared with the PSMG and D@G groups. Baseline FG levels were the main variable associated with the development of DM. In the subjects who had DM at baseline, glucose control did not change. The impact of PCSK9i on glucose metabolism should not be of concern when prescribing these therapies.

Keyphrases

type diabetes
glycemic control
low density lipoprotein
primary care
cardiovascular disease
blood glucose
blood pressure
adipose tissue
adverse drug